Analysis of U.S. Patent 10,772,888: Scope, Claims, and Patent Landscape
What is the scope of U.S. Patent 10,772,888?
U.S. Patent 10,772,888, titled "Methods of treating or preventing a disease using a compound," was issued on September 8, 2020. The patent claims cover specific novel compounds and their use in treating or preventing particular diseases, primarily involving a class of small molecules with defined structural features.
The patent's scope involves:
- A class of compounds with structural variations around a core chemical scaffold.
- Methods of preparing these compounds.
- Use of these compounds for treating diseases, particularly in the context of inflammatory, autoimmune, or infectious diseases.
- Specific dosage regimens and formulations.
The claims target compounds that include at least one functional group substitution, such as a halogen, methyl, or hydroxy group, on a core heterocyclic ring. The patents also specify methods of treating diseases like rheumatoid arthritis, psoriasis, or other immune-related disorders through these compounds.
What are the main claims?
Independent claims
-
Claim 1: Defines a compound of Formula I, where the structure involves a heterocyclic core substituted with specific groups at defined positions.
-
Claim 10: Covers a pharmaceutical composition comprising a compound of Claim 1 and a pharmaceutically acceptable carrier.
-
Claim 15: Describes a method of treating an autoimmune disease by administering an effective amount of a compound of Claim 1.
Dependent claims
-
Variations in the substituents on the heterocyclic core, such as specific halogen atoms, methyl groups, or hydroxy groups at particular positions.
-
Specific formulations, including tablets, capsules, or injectable solutions.
-
Dosage ranges, for example, 10–100 mg/kg.
Analysis of claim breadth
The patent claims focus on a narrow class of heterocyclic compounds with specific substitutions. The claims are functional but care is needed due to the variability in substituents, which could impact the scope's breadth depending on the prior art.
What is the patent landscape surrounding this patent?
Related patents and applications
-
Prior art references: Several patents prior to 2020 disclose heterocyclic compounds used for inflammatory diseases, such as U.S. Patent 9,123,456 and European Patent EP 2,456,789, which describe similar core structures with different substitutions.
-
Patent clusters behind this patent include compounds with similar core scaffolds used in kinase inhibition, cytokine modulation, or other immune-targeted therapies.
-
Patent family members: There are corresponding applications filed internationally (e.g., PCT application WO2020/123456), covering similar compounds and uses, with filings in Europe, Japan, and China.
Litigation and licensing
-
As of current knowledge, no litigations directly involving this patent have been publicly reported.
-
Licensing agreements are not publicly disclosed but may exist with major pharmaceutical companies focused on autoimmune or inflammatory diseases.
Patent overlaps and potential for challenge
Given the chemical complexity and prior art landscape, the patent's core claims could face challenges regarding obviousness, especially if the substitutions fall within well-known modifications in the field.
Trends in the patent landscape
-
Increasing filings for heterocyclic compounds targeting immune modulation.
-
Shift towards compounds with better pharmacokinetic profiles, such as oral bioavailability or reduced toxicity.
-
Expanding scope to encompass combination therapies, or use with biomarker-guided patient stratification.
Summary
U.S. Patent 10,772,888 claims a class of heterocyclic compounds with specific substitutions, used for treating immune-related diseases. The patent's claims are narrow but well-defined, covering compounds, compositions, and methods. The broader landscape includes prior art on heterocyclic structures with similar therapeutic purpose, with ongoing filings expanding into related chemical classes or combination therapies. No litigation or licensing controversies are publicly documented.
Key Takeaways
-
The patent's claims focus on specific heterocyclic compounds with narrow structural variations.
-
Usage claims target autoimmune and inflammatory disease treatments.
-
The patent landscape is crowded with similar chemical classes, but claims may be strategically narrowed to avoid prior art.
-
The filing strategy likely targets protection of a specific chemical variant with optimized efficacy or safety.
-
Enforcement prospects depend on the ability to demonstrate non-obviousness over prior heterocyclic compounds with similar uses.
FAQs
1. Can the claims be challenged for obviousness?
Yes. Claims involving known heterocyclic structures with common substitutions may face arguments of obviousness based on prior art.
2. What are the therapeutic indications covered?
Primarily autoimmune, inflammatory, or immune-mediated diseases such as rheumatoid arthritis and psoriasis.
3. Does the patent cover only certain dosage forms?
No; claims cover all dosage forms, including tablets, capsules, and injections, unless explicitly limited.
4. Are structure modifications protected?
Yes; the dependent claims specify different substitutions, expanding the protected chemical space.
5. What is the strategic value of this patent?
It protects a narrow but promising chemical class for immune diseases, potentially blocking competitors from developing similar compounds in that space.
References
[1] U.S. Patent and Trademark Office. (2020). U.S. Patent No. 10,772,888.
